



Contact:
Torben Jørgensen, CEO
Phone: +46 18 56 59 02,
torben.jorgensen@biotage.com

Biotage AB
Kungsgatan 76
SE-75318
Tel +46 18 56 59 00
www.biotage.com

Unique Parallel Peptide Synthesizer with Automated Microwave Technology offers "The Best of Both Worlds" for Peptide Chemists

Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, today announced the eagerly awaited global launch of the Syro Wave™, their new microwave and parallel peptide synthesizer. The Syro Wave™ is a result of the joint development project announced last year between Biotage and MultiSynTech. It combines the proven performance of the established MultiSynTech robotic synthesizer with Biotage microwave technology.

The Syro Wave™ peptide synthesis system is the only system on the market that offers both microwave and parallel peptide synthesis capabilities. To date peptide synthesis labs have been required to invest in both standalone parallel systems for productivity and cost efficiency, and standalone microwave systems for difficult or longer peptides. This results in increased demand on bench space, duplication of computer control systems, and multiple operating software platforms for chemists to learn and maintain. Biotage has addressed these shortcomings with the Syro Wave™, containing both parallel and microwave technologies on the same platform.

The new Biotage Syro Wave™ increases productivity, yield and purity while cutting costs and saving time. "At Biotage the focus is on developing technology to speed up and simplify experimental procedures while simultaneously driving down operating costs. Whether the customer is a Pharma development group, a CRO focused on cost and productivity or an Academic researcher focused on unique sequences, the Syro Wave™ fits," noted Scott Carr, Vice President Commercial Operations, Biotage.

For more information on the Biotage parallel Peptide Synthesizer system, please email product_info@biotage.com or visit www.biotage.com

Om Biotage

Biotage erbjuder lösningar, kunskap och erfarenhet inom analytisk kemi och läkemedelskemi. Kunderna består bland annat av de största läkemedels- och bioteknikbolagen i världen samt av ledande akademiska institutioner. Huvudkontoret ligger i Uppsala och företaget har kontor i USA, England och Japan. Biotage har 245 anställda och omsatte 394,1 MSEK under 2009. Biotage är noterat på NASDAQ OMX Nordiska börsen i Stockholm. Hemsida: www.biotage.com